Leerink Partners Maintains Outperform on Revolution Medicines, Raises Price Target to $171

Benzinga Newsdesk www.benzinga.com Positive 89.2%

Neg 0% Neu 0% Pos 89.2%

Leerink Partners analyst Jonathan Chang maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $147 to $171.